舒肝健脾法对溃疡性结肠炎肝郁脾虚模型大鼠的治疗作用研究被引量：9

导出

摘要目的:探讨舒肝健脾法(舒肝健脾颗粒)对溃疡性结肠炎肝郁脾虚模型大鼠的治疗作用及作用机制。方法:采用TNBS/乙醇溶液灌肠加束缚法制作溃疡性结肠炎(UC)肝郁脾虚大鼠模型,观察我院自制药舒肝健脾颗粒对大鼠体重、结肠组织学、局部结肠血管活性肠肽(VIP)和白介素10(IL-10)水平的影响。结果:模型对照组大鼠肠组织中VIP较正常明显降低(P<0.01),IL-10显著降低(P<0.01),舒肝健脾颗粒可以有效对抗肝郁脾虚模型大鼠的结肠组织中的VIP、IL-10水平的改变(P<0.01);能增加大鼠的体重,改善局部结肠黏膜的受损程度。结论:舒肝健脾法可有效治疗UC,其作用机制可能与参与调节神经-内分泌-免疫网络,促进抑炎因子的产生有关。

作者秦震声张燕生

机构地区北京中医药大学北京中医药大学东方医院

出处《中医研究》 2007年第5期13-16,共4页 Traditional Chinese Medicinal Research

关键词血管活性肠肽白介素溃疡性结肠炎/药物作用舒肝健脾法/药效学

分类号 R285.5 [医药卫生—中药学]

引文网络
相关文献

参考文献12

1王皓,欧阳钦,胡仁伟.三硝基苯磺酸结肠炎动物模型的建立[J].胃肠病学,2001,6(1):7-10. 被引量：177
2Blalock JE.Amolecular basic fcrbidi rectional communication between the immune and neuroendocrine system[J].Physiol Rev,1989,69(1):1-5.
3Besedovsky HO.Changes in blood hormones during the immune response[J].ProcSoc Exp Biol Med,1988,15(1):466-471.
4Fontana AF.Systhesis of IL-10 in the brain ofendotoxin-treated mice[J].J Immunol,1990,13(2):1610-1616.
5Dunn AJ.Cytokinsas a bridge between immune and neuroendocrine systems[J].Prog Neuroendocrinimmunol,1990,3:26-34.
6张松照,沈建根,潘建平.VIP选择性分化Th细胞的研究进展[J].国外医学（免疫学分册）,2005,28(2):65-68. 被引量：9
7Said S,Mutt V.Polypeptide with biological Activity:isolation from small Intestine[J].Science,1970,169:1217.
8Mukohyama,Ransj,Taniguchi.The inhibitory effect sofvaso actives intestinal petide and ituitaryadeny latecy clase-activaing polypeptide on osteoelast formation area sociated with upre gulation of ostepertege and down reglation of RANKL and RANK[J].Biocherionl and Biophysical Rear Communication,2000,271(1):158.
9Surrenti C,Renzi D,Garcea MR,et al.Colonic vasoactive intestinal polypeptide in ulcerative colitis[J].J Physiol Paris,1993,87(5):3072311.
10Asadullah K,Sterry w,Volk HD.Interleukin-10 therapymewof a new approach[J].Yharmacol Rev,2003,55.241-69.

二级参考文献41

1Turner D M ,Williams D M ,Sankaran D,Lazams M ,Sinnott P J and Hutchinson 1 V. An investigation of polymorphism in the interleukin - 10 gene promoter [ J ]. Eur J Immunogenet, 1997,24 : 1 - 8.
2Schaaf B M, Boehmke F, Esnaashari H,Seitzer U, Kothe H, Maass M,Zabel P and Dalho K. Pneumocoocal septic shock is associated with the interleukin - 10 - 1082 gene promoter polymorphism [ J ]. Am J Resp Crit Care Med ,2003 ,168 :476 - 480.
3Helminen M, Lahdenpohja N anti Hurmc M. Polymorphism of the interleukin - 10 gene is associated with susceptibility to Epstein - Barr vires infection [ J ]. J Infect Dis, 1999,180:496 - 499.
4Haanpaa M, Nurmikko T and Hurme M. Polymorphism of the IL- 10 gone is associated with susceptibility to herpes zoster[ J ]. Scand J Infect Dis,2002,34 : 112 - 114.
5Miyazoe S,Hamasaki K,Nakata K,Kajiya Y,Kitajima K,Nakao K, Daikoku M ,Yatsuhashi H,Koga M ,Yano M and Eguchi K. In uence of interleukin - 10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus, hepatitis B virus[ J ]. Am J Gastroenterol,2002,97:2086 - 2092.
6Moore KW,de Waal Malefyt R,Co . man RL,O 'Garra A Iuterleukin -10 and the interleukin - 10 receptor, Annu Rev Immunol, 2001, 19:683 -765. [01 ] Blumberg H,Conklin D,Xu WF et al, Interleukin 20 : discovery,receptor identi . cation, and role in epldennal function[J]. Cell, 2001,104:9 -19.
7Asadullah K,Sterry W, Volk HD. Interleukin - 10 therapy - review of a new approach[ J ]. Pharmacol Rev ,2003,55:241 - 69.
8Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M. Brennan FM. Two inhibitors of pro - in . ammatory cytokine, release, interleukin - 10 and interleukin -4, have contrastinge, ects on release of soluble p75 tumor necrosis factor receptoby cultured monocytes[ J]. Eur J Immunol, 1994,24:2699 - 705.
9Jenkins JK,Malyak M,Arend WP. The effects of interleukin 10 on interleukin - 1 receptor antagonist and interleukin - 1 betaproduction in human monocytes and neutrophils [ J ]. Lymphokine Cytokine Res, 1994,13 ;47 - 54.
10Chang CH, Furue M, Tamaki K. B7 - 1 expression of Langerhans cells is up -regulated by proin . ammatory cytokines, and is downregulated by interferon - gamma or by interleukin - 10[J]. Eur J Immunol, 1995,25:394 - 8.